Treprostinil hexadecyl ester clinical trials
Also written INS1009 and Treprostinil Palmitil.
How each study uses treprostinil hexadecyl ester is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the treprostinil hexadecyl ester studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test treprostinil hexadecyl ester, phase 3 first.
- Dec 2026An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Phase 2/3 · Insmed Incorporated
- Feb 2027A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentPhase 1 · Insmed Incorporated
Studies
Open first, then newest update. How each study uses treprostinil hexadecyl ester is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)RecruitingPhase 3Insmed IncorporatedNCT07234032Written as Treprostinil Palmitil Inhalation Powder
- A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentRecruitingPhase 1Insmed IncorporatedNCT07643155Written as Treprostinil Palmitil Inhalation Powder
- A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)RecruitingPhase 3Insmed IncorporatedNCT07805785Written as Treprostinil Palmitil Inhalation Powder
- Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)RecruitingPhase 3Insmed IncorporatedNCT07179380Written as Treprostinil Palmitil Inhalation Powder
- A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)RecruitingPhase 3Insmed IncorporatedNCT07481981Written as Treprostinil Palmitil Inhalation Powder
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Active, not recruitingPhase 2/3Insmed IncorporatedNCT05649748Written as Treprostinil Palmitil
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)CompletedPhase 2/3Insmed IncorporatedNCT05649722Written as Treprostinil Palmitil Inhalation Powder
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionCompletedPhase 2Insmed IncorporatedNCT05147805Written as Treprostinil Palmitil
- A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy ParticipantsCompletedPhase 1Insmed IncorporatedNCT07102316Written as TPIP F2
- A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung DiseaseCompletedPhase 2Insmed IncorporatedNCT05176951Written as Treprostinil Palmitil
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy ParticipantsCompletedPhase 1Insmed IncorporatedNCT06091579Written as Treprostinil Palmitil Inhalation Powder
- A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)TerminatedPhase 2Insmed IncorporatedNCT04791514Written as Treprostinil Palmitil
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call treprostinil hexadecyl ester · ClinicalTrials.gg INT015661
- UNII (FDA) 8GJK87S89FTREPROSTINIL PALMITILConfirmed FDA, Wikidata
- Wikidata Q27270416treprostinil hexadecyl esterConfirmed FDA, Wikidata
- DrugBank DB18792One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8GJK87S89F | TREPROSTINIL PALMITIL | Confirmed FDA, Wikidata |
| Wikidata | Q27270416 | treprostinil hexadecyl ester | Confirmed FDA, Wikidata |
| DrugBank | DB18792 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.